Study of Adzynma in cTTP patients
Part of Blood & lymphatic clinical trials.
This study observes children and adults with cTTP who have already used Adzynma. It aims to gather more information about the treatment's real-world effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with congenital thrombotic thrombocytopenic purpura (cTTP).
- You must have taken Adzynma (the approved treatment) for cTTP before, with at least one dose recorded in your medical records.
- You must not have a history of an ADAMTS13 inhibitor (antibodies that block the medication).
- You must not be taking any other investigational drug or be enrolled in another clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks back at medical records of people with a rare blood disorder called congenital thrombotic thrombocytopenic purpura (cTTP) who received a treatment called recombinant ADAMTS13 (rADAMTS13). The goal is to learn more about how this treatment works in real life.
This study looks at how patients with a rare blood disorder called congenital thrombotic thrombocytopenic purpura (cTTP) are doing while being treated with a replacement therapy called recombinant ADAMTS13. It aims to understand real-world experiences and outcomes.
This trial is looking at the immune system's role in thrombotic thrombocytopenic purpura (TTP), a rare blood disorder. It may help researchers understand the condition better and possibly improve future treatments.
This study looks back at medical records of people with immune-mediated thrombotic thrombocytopenic purpura (TTP), a rare blood clotting disorder. It aims to better understand the disease and how it is treated.
This trial studies whether taking aspirin can prevent TTP (thrombotic thrombocytopenic purpura) from coming back or worsening. It is for people with very low ADAMTS13 activity, a key blood marker tied to TTP risk.
This study is testing a new combination of medicines—immune-suppressing drugs, caplacizumab, and plasma infusions—to treat immune-mediated TTP without standard plasma exchange. It aims to make treatment simpler and potentially safer.
Hear when a new Thrombotic Thrombocytopenic Purpura (TTP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.